Actinium Says Phase 3 SIERRA Trial Results Of Iomab-B Shows Improving OS For AML Patients
RTTNewsApr 18 09:33 ET
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients With Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active re
PR NewswireApr 18 08:00 ET
Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. Amidst Groundbreaking Cancer Therapy Innovations
EvertiseApr 1 13:42 ET
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Centessa Pharmaceuticals (CNTA)
TipRanksApr 1 10:20 ET
Actinium's Phase 3 Trial Results Show Survival Benefit In Acute Myeloid Leukemia Patients; Stock Up
RTTNewsApr 1 10:04 ET
Actinium Pharmaceuticals Price Target Maintained With a $21.00/Share by Cantor Fitzgerald
Actinium Pharmaceuticals Price Target Maintained With a $21.00/Share by Cantor Fitzgerald
Dow JonesApr 1 08:32 ET
Express News | Cantor Fitzgerald Reiterates Overweight on Actinium Pharma, Maintains $21 Price Target
Moomoo 24/7Apr 1 08:24 ET
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)
TipRanksMar 28 07:30 ET
Express News | HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target
Moomoo 24/7Mar 26 12:14 ET
Actinium Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/26/2024 498.8% HC Wainwright & Co. → $50 Reiterates Buy → Buy 03/19/2024 259.28% Maxim Group $20 → $30
BenzingaMar 26 12:13 ET
Laidlaw's James Ahern Named to Crain's New York Notable Leaders in Finance 2024
NEW YORK, March 26, 2024 /PRNewswire/ -- Laidlaw & Co. Managing Partner James Ahern has been named one of Crain's New York's Notable Leaders in Finance for 2024. Mr. Ahern has been at Laidlaw for fou
PR NewswireMar 26 11:39 ET
Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning With Leading FDA Approved Commercial CAR T-Cell Therapy
Potential blockbuster opportunity for next-generation targeted radiotherapy conditioning with CAR T-cell therapy a multi-billion market with six FDA approved therapies totaling sales over $3.5 billio
PR NewswireMar 26 07:18 ET
Full-Life Technologies Achieves Regulatory Milestone With Nuclear Permit, Advancing Radioisotope Facility Construction
GEMBLOUX, Belgium, March 25, 2024 /PRNewswire/ -- Full-Life Technologies ("Full-Life"), today announced the recent achievement of its subsidiary "Full-Life Technology Europe" has obtained a Nuclear P
PR NewswireMar 25 20:00 ET
Earnings Week Ahead: Walgreens Boots Alliance, Carnival, GameStop and More
Seeking AlphaMar 24 08:01 ET
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Actinium Pharmaceuticals (ATNM)
TipRanksMar 20 12:50 ET
Maxim Adjusts Actinium Pharmaceuticals' Price Target to $30 From $20, Maintains Buy Rating
Actinium Pharmaceuticals (ATNM) has an average rating of buy and price targets ranging from $9.80 to $50, according to analysts polled by Capital IQ. Price: 7.85, Change: +1.31, Percent Change: +20.03
MT NewswiresMar 19 13:14 ET
Actinium Pharmaceuticals Price Target Raised to $30.00/Share From $20.00 by Maxim Group
Actinium Pharmaceuticals Price Target Raised to $30.00/Share From $20.00 by Maxim Group
Dow JonesMar 19 13:09 ET
Actinium Pharmaceuticals Is Maintained at Buy by Maxim Group
Actinium Pharmaceuticals Is Maintained at Buy by Maxim Group
Dow JonesMar 19 13:09 ET
Maxim Group Maintains Buy on Actinium Pharma, Raises Price Target to $30
Maxim Group analyst Jason McCarthy maintains Actinium Pharma with a Buy and raises the price target from $20 to $30.
Analyst UpgradesMar 19 12:59 ET
Actinium Spikes as H.C. Wainwright Highlights Buyout Prospects After Fusion Deal
Seeking AlphaMar 19 12:31 ET
No Data
No Data